Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
about
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
description
im Mai 2019 veröffentlicher wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2019
@uk
name
Third generation EGFR inhibito ...... d pre-clinical models of NSCLC
@en
Third generation EGFR inhibito ...... d pre-clinical models of NSCLC
@nl
type
label
Third generation EGFR inhibito ...... d pre-clinical models of NSCLC
@en
Third generation EGFR inhibito ...... d pre-clinical models of NSCLC
@nl
prefLabel
Third generation EGFR inhibito ...... d pre-clinical models of NSCLC
@en
Third generation EGFR inhibito ...... d pre-clinical models of NSCLC
@nl
P2093
P50
P1476
Third generation EGFR inhibito ...... d pre-clinical models of NSCLC
@en
P2093
Alessandro Romanel
Andrea Cavazzoni
Angela Falco
Costanza Annamaria Lagrasta
Daniele Cretella
Denise Madeddu
Elisabetta Barocelli
Federico Quaini
Graziana Digiacomo
Lisa Flammini
P356
10.1186/S13046-019-1240-X
P407
P577
2019-05-28T00:00:00Z